Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the efficacy and safety of mepolizumab 100 mg subcutaneous (SC) given every 4 weeks compared to placebo on the frequency of moderate and severe exacerbations in COPD subjects at high risk of exacerbations despite the use of optimized standard of care background therapy.
Critère d'inclusion
- Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations